Roche Cautions Against Viewing Liraglutide’s Risks as a Class Effect

Roche is cautioning analysts that its glucagon-like peptide-1 (GLP-1) analogue taspoglutide does not have the same risks as those discussed at a recent advisory committee meeting for Novo Nordisk’s GLP-1 Victoza. According to William Burns, CEO of Roche’s pharmaceutical division, GLP-1 products differ chemically, with one being of animal origin and two others that are chemically synthesized. Phase III data for taspoglutide are expected by the end of the year.
Drug Industry Daily